Dr. Lawal: PSMA therapy shows strong PSA responses; actinium may overcome resistance; future focus on dosing, combos, and reducing toxicity. Dr. Madan: bispecific T-cell engagers (STEAP1, KLK2, PSMA) show PSA responses with manageable CRS; cytokines key to boosting immunotherapy efficacy. Dr. Khan: neuroendocrine prostate cancer is rare, aggressive; chemo mainstay, IO under study; DLL3-targeted and T-cell therapies show emerging promise. Dr. Sonpavde: penile cancer—TIP is preferred (50% ORR); platinum+IO used; EGFR, HER2, TROP2 targets and InPACT trial under study. Dr. Adra: testicular cancer updates—miR-371 predicts relapse, RPLND may avoid chemo, new targets emerging; survivorship highlights long-term chemo effects. Panel: PSMA PET has limits—heterogeneous expression, SUV mean useful but hard to use; tumor volume not predictive; need better biomarkers and research.